GlassScriptPhysician profile
Lincoln Hernandez
NPI 1932137106
$45,862.40
in general payments reported to CMS, 2019-2025
24 companies · $872 in 2025
The $872 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,241 · 2021: $6,356 · 2022: $9,897 · 2023: $7,567 · 2024: $1,167 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,430 · Food and Beverage: $2,053 · Travel and Lodging: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,430.00 |
| Food and Beverage | $2,053.12 |
| Travel and Lodging | $1,123.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $43,754.62 | 2019-2025 | Epclusa |
| Phathom Pharmaceuticals, INC. | $415.82 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.60 | 2021-2025 | Xifaxan |
| Abbvie INC. | $235.79 | 2019-2025 | |
| Janssen Biotech, INC. | $182.32 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $167.48 | 2023-2025 | Ibsrela |
| Atmo Biosciences INC | $152.08 | 2025 | Atmo Biosciences |
| Regeneron Healthcare Solutions, INC. | $125.01 | 2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $121.64 | 2020 | |
| Boston Scientific Corporation | $119.38 | 2024 | Orbera Intragastric Balloon System |
| Allergan, INC. | $37.72 | 2019 | |
| Novo Nordisk INC | $32.75 | 2025 | Saxenda, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.04 | 2023 | Cyltezo |
| W. L. Gore & Associates, INC. | $26.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.40 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $22.17 | 2019 | |
| Medline Industries LP | $18.08 | 2022 | |
| Madrigal Pharmaceuticals | $16.51 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $15.14 | 2023 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $14.16 | 2021 | |
| Intercept Pharmaceuticals, INC. | $12.25 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lincoln Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.